Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
ETFs with OREX as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0%||BioShares Biotechnology Clinical Trials Fund (BBC)||N/A (N/A)|
Company Description (as filed with the SEC)
Orexigen® Therapeutics, Inc. ("Orexigen," "we," "our" and "us") is a biopharmaceutical company focused on the treatment of obesity. Our product, Contrave®, was approved in the United States by the U.S. Food and Drug Administration, or FDA, in September 2014 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index, or BMI, of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). In October 2013, we submitted an application for marketing authorization with the European Medicines Agency, or EMA, for Contrave under the name Mysimba(TM). ... More ...
Where does OREX fit in the risk graph?
|Annual EPS Est:||$-0.32|
|Quarterly EPS Est:||-0.16|